Sharemaestro company-news research for Apyx Medical Inc (APYX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest APYX news and sentiment
Apyx Medical Inc
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
9 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone35/100
→
Published 30-day score49/100
Latest source headline
Apyx Medical Corp (APYX-Q) Stock Price and News
The Globe and Mail · 01 Oct 2026 15:25
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
9 current stories are mapped specifically to APYX.
The score uses 4 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.051.
Confidence is 18/100, below the threshold for a firm score.
49/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
100%/100
Company news9 company stories
85/100
Story agreement15/100 difference
News history
Daily score and story count over 30 days
15 Sep30 Sep14 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.051 after freshness weightingSource breadth80
4 independent publishersCompany relevance100
share tied directly to this companyFreshness5
recency-weighted evidenceAgreement85
how closely stories agreePublisher mix57
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks24 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202649USD 2.59+1.6%
02 Oct 202649USD 2.55-13.9%
25 Sep 202646USD 2.96-3.3%
18 Sep 202650USD 3.06+5.5%
11 Sep 202650USD 2.9-4.9%
04 Sep 202650USD 3.05-1.0%
28 Aug 202652USD 3.08-1.3%
21 Aug 202654USD 3.12+3.0%
Provisional evidence
News subjects
What is shaping the score
Earnings503 stories · 33%
Analyst action612 stories · 22%
Market update502 stories · 22%
Regulatory and legal241 stories · 11%
Balance sheet431 stories · 11%
Source mix
Where the evidence comes from
TMX Newsfile241 stories · 11%
MT Newswires691 stories · 11%
Seeking Alpha431 stories · 11%
The Globe and Mail501 stories · 11%
GuruFocus501 stories · 11%
GlobeNewswire501 stories · 11%
Stock Titan501 stories · 11%
Recurring subjects
Subjects appearing most often
Life Sciences7Financial Markets4Earnings2Technology1Finance1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
05 May50 neutral12 Oct 03:37
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 12 Oct 03:37 | 49 | +0 | 17/100 (-8) | 10 (-1) | Provisional |
| 01 Oct 23:59 | 49 | -1 | 25/100 (-4) | 11 (+1) | Provisional |
| 29 Sep 23:59 | 50 | +6 | 29/100 (-5) | 10 (+3) | Provisional |
| 21 Sep 23:59 | 44 | +0 | 34/100 (+1) | 7 (+2) | Provisional |
| 20 Sep 23:59 | 44 | -6 | 33/100 (+17) | 5 (0) | Provisional |
| 16 Sep 23:59 | 50 | +0 | 16/100 (0) | 5 (0) | Provisional |
| 15 Sep 23:59 | 50 | +0 | 16/100 (-8) | 5 (-21) | Provisional |
| 02 Sep 23:59 | 50 | -2 | 24/100 (+2) | 26 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 9 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Regulatory and legal1 story
56.7%0.0%
Balance sheet1 story
32.8%0.0%
Analyst action1 story
0.0%10.5%
Each side uses the same scale: 0–56.7% of the retained directional evidence.
Where the influence comes from
56.7%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
Apyx Medical Corp (APYX-Q) Stock Price and News
This page provides stock price information and recent news headlines for Apyx Medical Corp (APYX-Q). It includes real-time stock data, volume summaries, and a list of news articles dating back to May 2026, highlighting the company's clinical study results, earnings calls, FDA clearances, …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides stock price information and recent news headlines for Apyx Medical Corp (APYX-Q). It includes real-time stock data, volume summaries, and a list of news articles dating back to May 2026, highlighting the company's clinical study results, earnings calls, FDA clearances, and board changes. The company profile details its focus on energy technology for cosmetic and surgical markets with its Renuvion® and J-Plasma® products.
- Published
- 01 Oct 2026 15:25
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife SciencesTechnology
—Unscored
Analyst actionNot used in direction
APYX Initiates Coverage On by Maxim Group -- Price Target Announ
Maxim Group has initiated coverage on Apyx Medical (APYX) with a "Buy" rating and a price target of $6.00. While the company's GF Score™ of 76/100 indicates strong growth and momentum potential, GuruFocus suggests the stock is currently 14.1% overvalued at $2.51, with a GF Value™ of $2.20…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Maxim Group has initiated coverage on Apyx Medical (APYX) with a "Buy" rating and a price target of $6.00. While the company's GF Score™ of 76/100 indicates strong growth and momentum potential, GuruFocus suggests the stock is currently 14.1% overvalued at $2.51, with a GF Value™ of $2.20. The article highlights Apyx Medical's strengths in growth and momentum but points out challenges in profitability and cash flow, advising caution for investors despite the positive analyst outlook.
- Published
- 29 Sep 2026 15:34
- News subject
- Analyst action
- Why this score
- Operating growth, Negative valuation view
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
69/100 tone
Analyst action
Maxim Initiates Apyx Medical at Buy With $6 Price Target
Maxim has initiated coverage on Apyx Medical (NASDAQ: APYX) with a "Buy" rating and a price target of $6.00. This positive analyst recommendation suggests a strong belief in the company's future performance. The article also provides recent news and financial details about Apyx Medical, h…
10.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Maxim has initiated coverage on Apyx Medical (NASDAQ: APYX) with a "Buy" rating and a price target of $6.00. This positive analyst recommendation suggests a strong belief in the company's future performance. The article also provides recent news and financial details about Apyx Medical, highlighting its focus on surgical aesthetics with products like Renuvion and J-Plasma.
- Published
- 29 Sep 2026 12:10
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 10.5% of directional evidence · 15.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
EarningsNot used in direction
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Apyx Medical Corporation announced results from a new clinical study published in Plastic and Reconstructive Surgery—Global Open, demonstrating Renuvion helium plasma radiofrequency technology's positive impact on skin quality. The study found significant increases in elastin, reduced inf…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Apyx Medical Corporation announced results from a new clinical study published in Plastic and Reconstructive Surgery—Global Open, demonstrating Renuvion helium plasma radiofrequency technology's positive impact on skin quality. The study found significant increases in elastin, reduced inflammation, and regenerative skin remodeling in treated human tissue, alongside high patient satisfaction and visible improvements in skin elasticity, radiance, and youthfulness. These findings provide biological evidence supporting Renuvion's clinical benefits beyond tissue contraction, suggesting its potential for comprehensive aesthetic procedures.
- Published
- 29 Sep 2026 12:00
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
EarningsNot used in direction
Every participant in Apyx Medical's study reported improved skin elasticity, radiance and youthfulness
Apyx Medical (APYX) announced positive results from a clinical study on its Renuvion helium plasma radiofrequency technology. The study, published in Plastic and Reconstructive Surgery—Global Open, demonstrated that Renuvion treatment led to a 30% increase in elastin fiber density and a 3…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Apyx Medical (APYX) announced positive results from a clinical study on its Renuvion helium plasma radiofrequency technology. The study, published in Plastic and Reconstructive Surgery—Global Open, demonstrated that Renuvion treatment led to a 30% increase in elastin fiber density and a 34% reduction in inflammation in treated tissue. All six participants who completed the study reported improved skin elasticity, radiance, and youthfulness, and expressed satisfaction with the results.
- Published
- 29 Sep 2026 07:00
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
43/100 tone
32.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 07:00
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 32.8% of directional evidence · 23.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Apyx Medical Corporation(NasdaqGS: APYX) added to S&P Global BMI Index
Apyx Medical Corporation (NasdaqGS: APYX) has been added to the S&P Global BMI Index, effective September 20, 2026. The company is a surgical aesthetics firm known for its Advanced Energy segment, which includes the Renuvion and J-Plasma technologies. Apyx Medical also has an OEM segment …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Apyx Medical Corporation (NasdaqGS: APYX) has been added to the S&P Global BMI Index, effective September 20, 2026. The company is a surgical aesthetics firm known for its Advanced Energy segment, which includes the Renuvion and J-Plasma technologies. Apyx Medical also has an OEM segment that designs and manufactures electrosurgical equipment.
- Published
- 21 Sep 2026 01:28
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.9d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
24/100 tone
The Rosen Law Firm is encouraging investors of Apyx Medical Corporation (NASDAQ: APYX) who suffered losses to secure counsel before the August 5, 2022, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Apyx made false and misleading statements about th…
56.7% of directional evidence
High story strength
Scoring detailsDirect company coverage
The Rosen Law Firm is encouraging investors of Apyx Medical Corporation (NASDAQ: APYX) who suffered losses to secure counsel before the August 5, 2022, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Apyx made false and misleading statements about the off-label use of its Advanced Energy products, leading to increased adverse event reports and potential regulatory scrutiny. Investors who purchased Apyx securities between May 12, 2021, and March 11, 2022, may be entitled to compensation.
- Published
- 20 Sep 2026 04:54
- News subject
- Regulatory and legal
- Why this score
- Legal or regulatory risk
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 58/100
- 30-day weight
- 56.7% of directional evidence · 24.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Market updateNot used in direction
Apyx Medical Corporation (APYX) Stock Price Prediction for 2026, 2030-2040
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 16 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
APYX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 79 older APYX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to APYX, but the headline and available text are not mainly about Apyx Medical Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of APYX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.